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ABSTRACT
Rheumatoid arthritis (RA) is a progressive chronic inflammatory disease affecting 0.5–1.0% of the adult population worldwide. Due to the damages 
caused by this autoimmune disease, new biologic therapies, particularly the biologic disease-modifying antirheumatic drugs (bDMARDs), are now 
being the treatment of choice in the management of RA. However, special precaution and prescreening before the usage of bDMARDs are needed to 
ensure better clinical response and avoiding risk of adverse event during treatment with the selected bDMARDs. In this review paper, we will provide 
overview on the incidence and pathogenesis of the disease, available pharmacological treatment and emphasizing special consideration in need on 
initiation of bDMARDs among RA patients. A literature review was performed by searching for relevant articles in Medline database through PubMed 
using medical subject headings terms and keywords: RA, bDMARDs, special consideration, tumor necrosis factor inhibitor, and non-tumor necrosis 
factor inhibitor. All papers reviewed were from 1999 to 2017 and were written in English. In this article, use of conventional synthetic DMARDs 
(csDMARDs), bDMARDs and special consideration to be taken upon initiation of biologic therapies in RA will be reviewed.
Keywords: Biologic therapy, Non-tumor necrosis factor inhibitors, Precaution, Prescreening, Rheumatoid arthritis, Tumor necrosis factor inhibitor.
INTRODUCTION
Rheumatoid arthritis (RA) is a progressive chronic inflammatory 
disease with which, if left untreated, 20–30% of patients would 
become permanently work disabled within 3 years of diagnosis. It is 
known to affect 0.5–1.0% of the adult population worldwide, and the 
overall prevalence of the disease for the adult population of Asia is 
reported between 0.2 and 0.3% [1-3]. This inflammatory autoimmune 
disease is chronic progressive symmetrical polyarticular joint disease, 
characterized by progressive destructions of the articular cartilage, 
bone, and non-articular muscular structures that can cause joint 
deformities. After a mean follow-up of 3.9 years, 47.5% of RA patients 
experienced at least one extra-articular or systemic manifestation. New 
treatment modalities by the initiation of targeted biologic therapies are 
recommended to for disease control, damage prevention, persevering 
affected joint function, increase in patients’ quality of life, and increase 
the possibilities to achieve complete remission of the disease [4]. The 
biologic disease-modifying antirheumatic drugs (bDMARDs) or known 
as the monoclonal antibody (mAb) therapies, which target directly to the 
specific cytokines cells and molecules of the disease pathophysiology, 
can be initiated either alone as monotherapy or as combination therapy 
with the conventional synthetic DMARDs (csDMARDs) therapy within 
the first 3 months of early RA diagnosis [5-7]. This review will provide 
an overview of the RA disease, the use of new mAb therapies in addition 
to the csDMARDs used in the management of RA, as well as suggestive 
prescreening test based on disease history or concurrent condition on 
selection of biologic treatment initiation in RA patient.
METHODOLOGY
Relevant articles were searched in Medline database through PubMed 
using medical subject headings terms and keywords: RA, bDMARDs, 
special consideration, tumor necrosis factor inhibitor, and non-tumor 
necrosis factor inhibitor. All papers reviewed were written in English, 
from 1999 to 2017. The articles focused on descriptive information on 
RA disease, treatment used in the management of RA including biologic 
mAb and prescreening on biologic treatment initiation.
OVERVIEW ON INCIDENCE OF RA
RA is a chronic autoimmune disease causing permanent disability that 
reduces patients’ quality of life overtime of the disease progression. RA 
is known to affect 0.5–1.0% of the adult population worldwide [1]. RA 
is more prevalent in females than males with female-to-male ratio of 
3:1 and with increasing age [8]. Studies have shown that the incidence 
of RA remained stable or increased over time, and the prevalence of 
RA is high in the general population [9]. Known as a multifactorial 
heterogeneous disease, RA has different incidence rate and prevalence 
across different populations and geographical area [2,3]. Studies on 
prevalence and incidence rates of RA in population of Asia consisting 
countries from Japan, China, Taiwan, Indonesia, and Philippine reported 
a prevalence of the disease between 0.2 and 0.3% [2]. It was observed 
that the prevalence of RA varies widely from population to population 
with the highest rate found among Pima Indians (5.3%) and Chippewa 
Indians (6.8%) and lowest rate in Asian countries. Prevalence among 
population from China and Japan is 0.2–0.3% [10]. The regional 
variation of RA prevalence may suggest role of genetic factor underlying 
susceptibility to the disease. In Malaysia, according to the Arthritis 
Foundation Malaysia 2007, RA affects 5 in 1000 Malaysians. The 
Rochester Epidemiology Project provides the most recent US data on 
the incidence of RA. It is observed that in a period of time from 1995 to 
2007, it was estimated 1.5 million of the United States (US) adults age 
more than 18 years old had RA and the RA incidence increased among 
women compared to men [8]. Published data showed that prevalence 
rate of RA is generally 2–3 times higher in female than male, and the 
prevalence increases with increasing age up to about eighth decade of 
life and peaks at around age of sixties. The incidence peaked earlier for 
women than men at about ages 55–64 years for women, compared with 
75–84 years for men [11,12].
Pathogenesis and extra-articular manifestation of RA
Basically, the first affected joint structure in RA is the synovium. 
Synovium is the synovial membrane lines within the joint capsule 
and produces the synovial fluid. The inner layer of the synovial 
membrane consists of two synoviocytes which are the macrophage-like 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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synoviocytes and fibroblast-like synoviocytes, and both are capable 
of expressing cytokines and degenerative enzymes. In the case of 
joint inflammation, the inflammatory arthritis leukocytes migrate 
from the blood vessels into the synovial lining and trigger release of 
inflammatory mediators and enzymes by cellular interactions. This 
synovial immunologic process and inflammation will lead to synovitis, 
irreversible damage to the cartilage and bone and contributes to 
systemic consequences of the disease [1,13].
It is suggestive that the development of RA is related to trauma, 
degeneration, abnormalities in biochemical pathways, autoimmunity, 
inflammation, and genetic polymorphisms. Environmental factors 
were found to trigger the disease, as well as social factors [13]. The 
interaction of genetics and environmental factors such as cigarette 
smoking, infection, or trauma can cause a breakdown of immune 
tolerance and synovial inflammation in a characteristic symmetric 
pattern [10]. The T-cells, B-cells, and coordinated interaction of pro-
inflammatory cytokines play important roles in the pathophysiology of 
RA. CD4 T-cells are activated to secrete interleukin (IL)-2 and interferon 
gamma (tumor necrosis factor [TNF]-γ) for infiltration into the 
synovial membrane. These cells later activate synovial macrophages 
and fibroblasts and hence lose responsiveness to T-cell activities in 
the course of RA. The B-cells may serve as antigen- presenting cells, 
together with the production of autoantibodies such as rheumatoid 
factors. Autoantibodies can form larger immune complexes that 
can further stimulate pro-inflammatory cytokines, TNF-α through 
complement, and Fc-receptor activation [14].
Cells of innate immune system including macrophages, neutrophils, 
and mast cells also play a pivotal role in pathophysiology of synovial 
inflammation in RA. Neutrophils that present in synovial fluid will 
synthesize inflammatory prostaglandins, proteases, and reactive oxygen 
intermediates. Besides macrophages involvement in osteoclastogenesis, 
macrophages also secrete pro-inflammatory cytokines such as TNF-α, 
IL-1, and IL-6. These cytokines are key mediators of cell migration and 
inflammation in RA. TNF-α activates cytokines, chemokine expression, 
endothelial cell adhesion molecules, protects fibroblast, promotes 
angiogenesis, and suppresses regulatory T-cells. Whereas, IL-6 
promotes leukocyte activation, autoantibody production, contributes 
to anemia, and dysregulation of lipid metabolism. Both TNF-α and IL-6 
will amplify osteoclast activation and differentiation [10].
Although RA primarily affects the joints, the disease process can 
involve other organ systems. Involvement of other organ systems is 
defined as extra-articular manifestation involving systemic effects 
or all conditions and symptoms which are not directly related to the 
locomotor system [13,15]. A retrospective analysis done by Hochberg 
et al. on the incidence and prevalence of extra-articular and systemic 
manifestations in a cohort of newly diagnosed patients with RA in 
the US, 47.5% of 16,752 patients with RA experienced at least one 
extra-articular or systemic manifestation with a mean follow-up of 
3.9 years diagnosis [16]. Extra-articular manifestations identified were 
rheumatoid nodules, vasculitis, pericarditis, keratoconjunctivitis sicca, 
uveitis, Felty’s syndrome, scleritis, pericarditis, and rheumatoid lung 
disease [17]. Whereas, for systemic manifestations identified include 
non-specific features such as asthenia, fatigue, muscle weakness, 
fever, anorexia, anemia, osteoporosis, weight loss, acute-phase protein 
production, cardiovascular disease (CVD), and depression [18].
Epidemiologic studies of comorbidities and extra-articular manifestations 
in RA patients have emphasized that both were associations and 
predictors to increased morbidity and premature mortality in RA 
patients [19-21]. A cross-sectional, international, and multicenter 
study, COMORA (Comorbidities in RA) of 3920 RA patients recruited 
from 17 countries on five different continents, revealed high prevalence 
associated comorbidities were psychiatric disorder, mainly depression, 
gastrointestinal diseases, pulmonary diseases, especially chronic 
obstructive pulmonary disease (COPD) and asthma, ischemic CVD, 
hepatitis B, and hepatitis C infections, and solid malignancies, excluding 
basal cell carcinoma [22]. When compared to RA patients without 
extra-articular manifestation, the RA patients with extra-articular 
manifestation had higher mortality rates of 2.5 (95% CI: 1.4–4.0) [23]. 
A study by Norton et al. have shown on average, RA patients had 0.9% 
comorbidities at baseline (95% CI 0.8–1.0%), and after 5 years from 
diagnosis increases to 1.8 (95% CI 1.6, 1.9) and 2.3 (95% CI 2.1, 2.5) 
after 10 years. With the increasing comorbidities in RA patients, this 
study has found that comorbidity impacts on mortality, functional and 
work disability, but not on structural damage or disease activity of RA 
patients [24].
OVERVIEW OF TREATMENT IN RA
According to the European League Against Rheumatism (EULAR) 
recommendations for the management of RA with synthetic and 
bDMARDs on the 2016 updates, on classifying the DMARDs, the task 
force adhered to the previously proposed new nomenclature of DMARDs 
as tabulated in Table 1 [5,25]. The new nomenclature of the DMARDs 
provides mechanistic distinction based on the drugs mechanism of 
action. The chemical compounds of the conventional synthetic DMARDs 
(csDMARDs), are small molecules that can enter the cell and interact 
Table 1: The nomenclature types of treatments for RA
DMARDs
sDMARDs bDMARDs







Leflunomide Baricitinib Costimulation inhibitor
Abatacept







DMRDs: Disease-modifying antirheumatic drugs, RA: Rheumatoid arthritis, TNF: Tumor necrosis factor, TNFi: Tumor necrosis factor inhibitors, csDMARDs: Conventional 
synthetic disease-modifying antirheumatic drugs, sDMARDs: Synthetic disease-modifying antirheumatic drugs, bDMARDs: Biologic disease-modifying antirheumatic 
drugs, IL-6: Interleukin-6
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with the intracellular structures. Whereas, the targeted biological 
agents, either the targeted synthetic DMARDs (tsDMARDs) or the 
Biological Originator DMARDs and Biosimilar DMARDs, are engineered 
to target specifically well-defined functional moiety either as inhibitor 
of a signal transduction pathways or activate sites on extracellular or 
cell membrane molecules [25].
csDMARDs therapies in RA
The goal of therapy in managing RA is mainly to control disease activity, 
reduce joint damage, and improve patients’ quality of life. Earlier 
treatment modalities for RA, in the 1980s, start with giving support 
through physical therapy and non-pharmacological interventions. 
Later, pharmacological interventions are initiated with the use of 
aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) for 
symptomatic control, followed with a single antirheumatic agent or 
the DMARDs [26]. However, in the 1990s, it was found that after 1 year 
early intervention with DMARDs, treatment and management of RA 
was more effective in terms of slowing down disease progression as 
compared to treatment with NSAID alone [27]. DMARDs were then 
known as an agent that was able to suppress the acute phase responses, 
inhibit joint destruction, and reduce autoantibody levels in RA. 
Inverting the therapeutic pyramid in managing RA was proposed as the 
new approach at that time to start using DMARDs as early as possible 
or at a disease duration of <6 months. The first 6 months of RA disease 
is established as a window of opportunity for treatment given to benefit 
and effective in controlling disease progression at long term [28,29].
Better clinical outcomes are achieved with suppressing disease 
progression with early DMARD intervention rather than following 
the previous pyramid approach [30]. The treatment approach 
used in RA patient was maintained for long periods of time 
[4,26,31]. Available csDMARDs are gold salts, methotrexate (MTX), 
sulfasalazine, chloroquine, hydroxychloroquine (HCQ), leflunomide 
(LEF), cyclosporine-A, azathioprine, d-penicillamine, and minocycline. 
DMARDs were previously termed as slowly acting antirheumatic drugs 
due to their relatively long treatment effect or lag time that occurs only 
after 3–6 months on starting the medication [32]. To overcome lag time 
of DMARD to take effect, glucocorticoid, a strong anti-inflammatory 
agent or an analgesic medication is required as a bridging therapy for 
at least 4–6 weeks duration, to rapidly control inflammation, pain, and 
associated symptoms during RA disease flares [33].
Apart from the inversion of the pyramid for the treatment management 
of RA, combination of DMARDs is one of the recommendations for 
patients with symptomatic early RA suggested in the American College of 
Rheumatology (ACR) guideline for the treatment of rheumatoid arthritis 
[34]. Combination therapy was long discussed in the late 1990s due to 
evidence in long-term failure of using single-drug therapy despite early 
intervention with DMARDs in RA. The purpose of combination therapy is 
mainly to increase drug efficacy and minimize risk of drug toxicities using 
DMARDs targeting different site and mechanism of action. Selection of 
doses in combining therapy either in double or triple therapy depends 
either to decrease drug toxicity using lower doses of toxic DMARD drugs 
or using higher doses of toxic DMARDs or drugs to diminish active RA 
disease [31]. Combination of DMARDs either as a double or triple therapy 
most commonly includes MTX as the dominant or anchor DMARD that 
shows good efficacy with tolerable toxicity [35], slow down radiological 
damage, and reduce RA mortality [26]. According to the 2015 update 
of the 2008 ACR recommendations for the use of DMARDs and biologic 
agents in the treatment of RA, examples of double therapy are MTX + HCQ, 
MTX + LEF, MTX + sulfasalazine (SSZ), and SSZ + HCQ. Whereas, for triple 
therapy of csDMARDs is MTX + HCQ + SSZ [36]. These combinations of 
DMARDs are recommended for early RA patients with moderate or high 
disease activity accompanied with poor prognosis features, as well as the 
established RA patients with low or moderate to high disease activity 
with poor prognosis features to achieve complete remission. Recent 
updates in the management of early RA and established RA permit the 
combination with a biologic therapy either a TNF inhibitors (TNFi) or 
a non-TNFi, either with or without MTX based on the agreement of the 
expert panels on the superior efficacy of treatment combination over 
a biologic monotherapy [25,34]. MTX in known to exhibit synergistic 
effect when used in combination with other csDMARDs or bDMARDs 
specifically the TNFi and IL-6 inhibitor which also suggests reduced of 
immunogenicity effect of the biologic therapy [37-39].
bDMARDs therapies in RA
The emergence of biologic targeted therapies in the management of RA has 
shift the current practice of RA managed care for tight control and treat-
to-target approach. bDMARDs have shown evidence in improving signs 
and symptoms of the disease, positive radiological progression, improve 
patient-reported outcomes in terms of gaining higher quality of life, and 
achieving disease remission or low disease activity [29,40]. However, RA 
in acknowledge as a disease that acquires high cost in terms of medication 
procurement and availability when biologic therapies or new treatment 
modalities are added to patients’ treatment regimen. Therefore, in 
accordance to the latest 2016 updates in the EULAR recommendation for 
the management of RA, treatment of RA patient should aim at the best 
care and based on shared decision between the patient and health-care 
practitioner, specifically the rheumatologist. Selection of treatment in 
managing RA should be based on disease activity, progression of structural 
damage, comorbidities, and safety issues [25].
Biologics are large molecule, protein-based drugs targeting and identifying 
the cell subsets, and cytokines causing inflammatory and destructive 
components in RA. Cytokines modulation of rheumatoid synovitis is either 
the inhibition of the dominant pro-inflammatory cytokines such as the 
TNF-α, IL-1, IL-6, and IL-15 or the augmentation of the inadequate anti-
inflammatory activity of certain cytokines or naturally occurring cytokines 
inhibitors. Currently, there are several types of biologic approved for RA. 
The classification of these biologics depends on which target molecules in 
their mechanism of actions as listed in Table 2.
TNFi
The TNF-α is one of the proinflammatory cytokines which is the 
mediators of inflammation in RA. It is produced by macrophages, T-cells, 
mast cell, the natural killer cells, fibroblast, adipocyte, and the dendritic 
cells. It is usually inactive but can be induced by bacteria, viruses, tumor 
cells, trauma, and other exogenous stimuli through posttranscriptional 
regulation of gene expressions. When in high concentrations of TNF-α, it 
may lead to inflammation and organ injury [41]. The TNF-α is a trimeric 
molecule with two bioactive forms, membrane-bound TNF-α and soluble 
TNF-α. It is mediated through two types of receptors which are the 
TNF receptor 1 (TNFR1) and TNFR2. TNFR1 is expressed on most cells 
except the endothelial and hematopoiesis cells which are expressed by 
the TNFR2. The TNF-α or known as the soluble TNF (sTNF) activation 
is mediated through two pathways either by the activation of nuclear 
factor-kappa B (NF-kB) cells or the caspase-8-dependent apoptosis or 
the caspase-3-dependent apoptosis. The activation of the NF-kB acts as 
the transcriptional activators and induces the transcription factors can 
induce other inflammatory cytokines, namely the IL-6, IL-8, synergize with 
interferons, and T-cells activation causing inflammation [41,42]. Blockade 
of the excessive cytokines TNF-α is beneficial to halt inflammation and 
prevent immune activation in RA disease.
Currently, there are five TNFi for the treatment of RA, approved by the Food 
and Drug Administration and the European Medicines Agency. The TNFi 
are the infliximab, adalimumab, etanercept, golimumab, and certolizumab 
[43]. Infliximab is a chimeric mAb with the variable region or fragment 
antigen binding (Fab’) of mouse origin and the Fc region of human origin. 
Whereas, adalimumab and golimumab are fully humanized IgG1 TNFi 
mAbs. Infliximab, adalimumab, and golimumab are IgG1 antibodies that 
are capable for complement fixation and receptor binding at constant 
region (Fc). The three biologic agents bind both the transmembrane TNF 
(tmTNF) and the sTNF. Certolizumab which is a humanized Fab’ fragment 
bound to polyethylene glycol (PEG) without the Fc region and has higher 
binding affinity for TNF-α. The PEG component reduces immunogenicity, 
not causing antibody-dependent cell-mediated cytotoxicity, and prolongs 
its pharmacological availability in the system [42,44]. Etanercept is a 
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fusion protein composed of human TNFR2 fused to the Fc region of the 
human IgG1. It is the only TNFi that can bind and neutralize both TNF-α 
and a ligand of the lymphotoxin family. Etanercept binds and inactivates 
sTNF but not the tmTNF [41,42,44]. Pharmacokinetic characterization 
for TNFi is presented in Table 3.
Non-TNFi
The 2013 update of the EULAR recommended the use of non-TNFi 
bDMARDs, in cases of RA patients responding insufficiently to MTX 
and/or other csDMARD strategies, with or without glucocorticoids or 
the TNFi bDMARDs, and should be commenced with MTX to reduce 
Table 3: Characterization of TNFi
TNFi Infliximab Adalimumab Golimumab Certolizumab Etanercept
Abbreviation IFX ADA GOL CER ETA
Type of agent Immunosuppressive agents
Structure Chimeric Mab Fab’ domain of mouse 
origin and Fc region of human origin
Fully Human Fully Human Humanized Fab’ 
fragment PEGylated
Fusion protein between 
human IgG1 at Fc 
region and TNFR2




5–6 days 2–7 days 2–6 days 1–2 days







(SC): 3–5 days (68 h)
TNF: Tumor necrosis factor, Mab: Monoclonal antibody, Fab’: Fragment antigen-binding, IgG1: Immunoglobulin G1, TNFR2: Tumor necrosis factor receptor 2, 
IV: Intravenous, SC: Subcutaneous
Table 2: Biologic therapies used in the treatment of RA
Biologic agent Type Mechanism of action Available route Suggested dose
Infliximab Chimeric antibody Fab’ 
domain mouse origin, Fc 
domain human origin
Inhibit TNF-α Intravenous (IV) 3 mg/kg, infusion at week 0, 2, 6, 
then every 8 weeks
Adalimumab mAb fully human igG1 
antibodies
Inhibit TNF-α Subcutaneous (SC) SC 40 mg every 
2 weeks (fortnightly)
Golimumab mAb fully human IgG1 
antibodies
Inhibit TNF-α Subcutaneous (SC)/
intravenous (IV)
SC 50 mg monthly or 4 weekly
Certolizumab 
pegol
mAb humanized Fab’ fragment 
bound to PEG
Inhibit TNF-α Subcutaneous (SC) Loading dose SC 400 mg at week 
0, 2, and 4, maintenance dose SC 
200 mg every 2 weeks or SC 400 
mg every 4 weeks
Etanercept Recombinant protein (TNF 
receptor p75-Ig) fusion 
protein between human IgG1 
Fc tail and TNF receptor
Inhibit TNF-α Subcutaneous (SC) SC 50 mg weekly
Tocilizumab Humanized anti-IL receptor 
antibody
IL-6 receptor blocker Intravenous (IV)/
subcutaneous (SC)
IV infusion 4 mg/kg every 
4 weeks followed by an increase 
to 8 mg/kg every 4 weeks SC 162 
mg given once weekly 
Sarilumab mAb IL-6 receptor blocker Subcutaneous (SC) SC 200 mg once every 2 weeks or 
fortnightly
Rituximab Anti-CD20 mAb Block CD20 B-cell, depletes 
B-cells but not plasma cells up 
to 6–12 months
Intravenous IV infusion 1 g at day 0 and day 
14 given 6–12 months
Confirmed in RA seropositive for 
RF and/or anti-CCP antibodies
Abatacept Recombinant 
protein - cytotoxic T 
lymphocyte antigen 4 
immunoglobulin (CTLA4-Ig)
T-cell costimulation blocker
Block interaction between 
CD80 and CD86 on 
antigen-presenting cells and 
CD28 ligands on T-cells
Intravenous (IV)/
subcutaneous (SC)
IV infusion initial dose give at 2 
and 4 weeks, then every 4 weeks 
IV dose based on weight:
<60 kg=500 mg
60–100 kg=750 mg
More than 100 kg=1000 mg
SC 125 mg weekly 




IL-1 receptor inhibitors Subcutaneous (SC) SC 100 mg once daily (OD)
Tofacitinib JAK inhibitors JAK1 and JAK 3 inhibitor, 
interfering with the JAK-STAT 
signaling pathway
Oral (PO) PO 5 mg twice daily (BD)
Baricitinib JAK inhibitors Selective JAK1 and JAK2 enzymes 
inhibitor, interfering with the 
JAK-STAT signaling pathway
Oral (PO) PO 4 mg once daily (OD)
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treatment failure due to immunogenicity issues [5]. Non-TNFi when 
given in combination with MTX had shown improvements in RA signs 
and symptoms, physical function, health status, and progression of joint 
damage, therefore, are useful alternatives in patients with long-standing 
RA who have an inadequate response to TNFi [39]. The non-TNFi 
approved for the treatment of RA include abatacept, a T-cell inhibitor, 
Table 4: List of screening based on disease history or concurrent condition on biologic treatment selection or initiation for RA patient
Disease history or concurrent 
condition
Laboratory test/suggestion on vaccination Advice on treatment selection
TBC signs and symptoms Tuberculin skin test/Mantoux test interferon-gamma 
release assays (IGRAs) test
Provide TBC (TB) treatment on confirmation of 
active TB 
Latent TBC infection Tuberculin skin test/Mantoux test Interferon-gamma 
release assays (IGRAs) test
Provide TB prophylactic treatment with isoniazid 
on suspected latent TBC infection 
History of malignancy Duration of disease more or equal to 5 years Initiate biologic if solid malignancies or NMSCs 
have been treated for more than 5 years Caution 




Close monitoring of viral load and cluster of 
differentiation antigen 4 (CD4) count
Tumor necrosis factor inhibitor (TNFi) should be 
used after weighing the benefit to risk ratio for 
HIV-positive patients
Non-TNFi to be used cautiously
Varicella zoster or Herpes 
zoster
Varicella zoster virus antibody test Contraindicated in active zoster infection 





Recommended before initiating biologic therapy 
or currently on biologic therapy
Influenza vaccination Recommended before initiating biologic 
therapy or currently on biologic therapy Annual 
vaccination
Hepatitis B vaccination Recommended in high risk of hepatitis 
presented (intravenous drug abuse, multiple 
sex partners in previous 6 months, health-care 
personnel)
Recombinant vaccine Human 
papillomavirus (HPV) 
vaccination
Recommended before initiating biologic therapy 
or currently on biologic therapy
Live attenuated vaccine Herpes zoster vaccination Recommended before initiating biologic therapy.
Not recommended for TNFi and non-TNFi 
biologics currently on biologic therapy
Pregnancy (women of 
child-bearing age)
Pregnancy test Teratogenic risk: Data insufficient to claim safety
Limited human data
Animal data suggest low risk
Contraindicated if use in combination with MTX
Heart failure symptoms Electrocardiography (ECG) TNFi contraindicated in congestive heart failure 
or in moderate-to-severe heart failure (NYHA 
class III-IV, EF<50%)






Hepatitis B Hepatitis B surface antigen (HBsAg)
Antibody to hepatitis B surface antigen (anti-HBs)
Antibody to hepatitis B core antigen (anti-HBc)
Continue immunosuppressive treatment as 
recommended in patients without this condition
Safe to use in combination with effective antiviral 
therapy or prophylactic antiviral therapy
Transaminitis Liver function test (LFT) Close monitoring in elevated aminotransferase 
three times the upper limit of normal (ULN)
Discontinue if aminotransferase increased 
5 times the ULN
Baseline inflammatory markers Erythrocyte sedimentation rate (ESR)
C-reactive protein (CRP)
On treatment initiation and every follow-up visit
Other baseline laboratory tests Full blood count (FBC)
Fasting blood sugar (FBS)
Renal profile
Lipid profile
Before and during TNFi treatment within 1st 
month of treatment initiation and repeated 2 to 3 
months during treatment.
To perform on each infusion, infliximab-treated 
patients.
IGRA: Interferon-gamma release assays, TB: Tuberculosis, CD4: Cluster of differentiation antigen 4, TNFi: Tumor necrosis factor inhibitor, HIV: Human 
immunodeficiency virus, HPV: Human papillomavirus, MTX: Methotrexate, ECG: Electrocardiography, NYHA class: New York Heart Association Functional Classification, 
EF: Ejection fraction, HBsAg: Hepatitis B surface antigen, Anti-HBs: Antibody to Hepatitis B surface antigen, Anti-HBc: Antibody to Hepatitis B core antigen, LFT: Liver 
function test, ULN: Upper limit of normal, ESR: Erythrocyte sedimentation rate, CRP: C-reactive protein, FBC: Full blood count, FBS: Fasting blood sugar
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tocilizumab, an IL-6 inhibitor, rituximab, a B-cell indicator, anakinra, 
an IL-1 inhibitor, tofacitinib, janus kinase inhibitor, and secukinumab, a 
fully human antihuman IL-17A mAb.
SPECIAL CONSIDERATION IN USING BDMARDS THERAPIES
Reactivation of latent tuberculosis (TBC) is a well-known fact in TNFi 
usage. The occurrence of latent TBC or the incidence rate ratio is 
higher in infliximab-treated patient, followed by adalimumab-treated 
patient as compared to etanercept-treated patient. Proportionate to the 
incidence of latent TBC per event per 1000 patient-years was reported 
as 1.5, 0.9, and 0.5 events for infliximab, adalimumab, and etanercept, 
respectively [45]. The mean onset for the development of TBC was 
found much more earlier in infliximab which is 12 weeks after initiation, 
30 weeks for adalimumab, and a total of 46 weeks for etanercept [46]. 
All patients in TNFi should be monitored for incidence of latent TBC at 
least for an annual screening despite initial screening done on initiation 
of TNFi treatment [47].
Based on the observational databases available for incidence of 
malignancy or cancer in RA patient treated with biologic TNFi, 
lymphoma and non-melanoma skin cancers (NMSCs) were found to have 
increased risk and risk of frequent incidence in RA patients compared 
to the general population [41]. A study by Elandt and Aletaha [48] 
suggested a generic stepwise approach for the management of patients 
with a rheumatic condition requiring immunosuppressive treatment 
in the context of a current or past malignancy. At least a minimum of 
2 years for a complete remission of a low-risk malignant disease is 
required before decision on type of immunosuppressive drug to be 
used in patients with a history of cancer. Whereas, for lymphomas, 
carcinomas of the breast, prostate, or colon or large symptomatic renal 
carcinomas of more than 5 cm, 5 years duration of complete remission 
of the malignancy disease is desirable. Common immunosuppressive 
drug used in rheumatic patient with a history of cancer are MTX, 
sulfasalazine, chloroquine, HCQ, cyclosporine, and mycophenolate 
mofetil. Whereas for biologic therapy, the TNFi are used, but caution 
is needed with close monitoring of risk of cancer development for all 
immunosuppressive agents selected [48-50].
Stringent patient screening before initiating a bDMARD is required 
and necessary to the best of effort in avoiding possible infectious 
complication or malignancy development [51,52]. List of screening 
based on disease history or concurrent condition and summary on 
advice, caution to be considered, and recommendation on treatment 
selection or initiation is simplified as in Table 4. Biologic therapy is 
large molecular protein structures that can provoke the development 
of antidrug antibodies (ADAbs) which associated to immunogenicity 
that can cause loss of response or reduced efficacy of the biologic 
treatment. Immunogenicity is the development of unwanted immune 
response against foreign protein introduced to the body system [43,53]. 
Studies have demonstrated that comedication of a biologic with MTX 
reduces immunogenicity. As an example, by concomitant MTX therapy 
in the treatment regimen of infliximab, it decreased the development 
of antibodies against infliximab which delayed reduction of serum 
infliximab concentrations as well as reducing the incidence of infusion 
reactions [54-56]. In a study among RA patient, the cumulative 
incidence of antibody formation was 6% and 12 patients treated 
with only adalimumab was found having antibody positive against 
adalimumab compared to patients with comedication with MTX. Similar 
to golimumab, without adding MTX to the treatment regimen, 30% 
reduction of golimumab serum concentration were found compared to 
patient received MTX combination with golimumab [57,58].
CONCLUSION
Emergence of new treatments in managing RA is evidently improved 
the patients’ quality of life and reduced burden or social impact caused 
by the autoimmune disease. Selection of treatment either using the 
conventional or bDMARDs should be done appropriately to prevent 
further progression of bone destruction in patient, achieving remission 
state with tolerable side effects while on treatment. For long-term safety, 
risk-benefit evaluation should be done thoroughly before initiation 
of bDMARD, and frequent monitoring is compulsory to reduce risk of 
infection and malignancy during commencement of treatment with 
bDMARDs. In view of the development of immunogenicity or formation 
of antibodies while on bDMARDs that can cause loss of response or 
ineffectiveness of treatment, identifying the factors contributing this 
issue may assist in personalizing bDMARDs selection for each individual 
RA patient. Incorporating pharmacokinetic measurement of bDMARD 
trough levels and the ADAb level may suggest a clear treatment strategy 
or algorithm to overcome issues of bDMARDs non-responsiveness 
among affected primary and secondary non-responders’ RA patients.
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